Daily parathyroid hormone (PTH) is approved by the FDA for the treatment of osteoporosis.
This study will evaluate the safety and effectiveness of PTH when given once a week.
Phase:
Phase 3
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)